About
Johnson & Johnson Innovation (JJDC) is the strategic venture capital arm of Johnson & Johnson. JJDC pursues opportunities to solve critical healthcare needs. Its portfolio companies benefit from the full global capabilities of Johnson & Johnson as JJDC collaborates to drive innovation. JJDC finds transformative ideas and helps them mature into real solutions for todays patients. Guided by a clear, consistent investment strategy aligned with scientific goals, JJDC works hand-in-hand with partners to navigate the path to creating breakthrough health innovations. JJDC invests across sectorspharmaceuticals, medical devices, and consumer healthcareand at all stages, from seed-level startups to Series B and beyond. JJDC also makes private investments in public equity. All of its portfolio companies receive the same unwavering commitment. JJDC takes a long-term approach, deploying the full capabilities of the Johnson & Johnson family of companies, including discovery, clinical development, regulatory affairs, manufacturing and commercialization. JJDC's team includes leaders in the healthcare and technology communities, many with deep R&D experience.
Portfolio
Investor Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Johnson & Johnson Innovation's primary investment focus?
- Johnson & Johnson Innovation (JJDC) is the strategic venture capital arm of Johnson & Johnson, focusing on opportunities to solve critical healthcare needs across pharmaceuticals, medical devices, and consumer healthcare sectors.
- Can you name some notable portfolio companies of Johnson & Johnson Innovation?
- Notable portfolio companies include Orasis Pharmaceuticals, which received a $78 million investment in October 2024, and V-Wave, which secured $98 million in September 2020. For a complete list, please refer to startupim data.
- What is Johnson & Johnson Innovation's investment stage preference?
- Johnson & Johnson Innovation invests at all stages, from seed-level startups to Series B and beyond, and also makes private investments in public equity. Their investment history includes Seed, A Round, B Round, C Round, D Round, E Round, and F Round.
- Has Johnson & Johnson Innovation had any significant exits from its portfolio?
- Yes, Johnson & Johnson Innovation has had several exits. V-Wave was acquired by Johnson & Johnson in August 2024 for $600 million, and CartiHeal was acquired by Bioventus in May 2022 for an undisclosed amount.
- Does Johnson & Johnson Innovation act as a lead investor in its rounds?
- Johnson & Johnson Innovation has acted as a lead investor in some rounds, for example, leading a $5 million investment in OrthoSpin in March 2020 and a $2.6 million investment in Techsomed in May 2019.
- What is the geographic focus of Johnson & Johnson Innovation's investments?
- While Johnson & Johnson Innovation is headquartered in the United States, the provided data indicates investments in Israeli companies, such as Orasis Pharmaceuticals and Discure Technologies.
- When did Johnson & Johnson Innovation make its most recent investment, according to startupim data?
- Johnson & Johnson Innovation's most recent investment, according to startupim data, was in Orasis Pharmaceuticals in October 2024, amounting to $78 million.
- What kind of support do portfolio companies receive from Johnson & Johnson Innovation?
- Portfolio companies benefit from the full global capabilities of the Johnson & Johnson family of companies, including discovery, clinical development, regulatory affairs, manufacturing, and commercialization.